# Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

> **NCT04771078** · — · AVAILABLE · sponsor: **Celgene**

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Nonconforming idecabtagene vicleucel

## Key facts

- **NCT ID:** NCT04771078
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771078, "Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04771078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*